June 24, 2008 — RegeneRx Receives First Patent on TB4's Ability to Repair Lung Damage Resulting from Infections and Other Disorders - RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) announced that it has received an Australian patent for the use of TB4, its derivatives, analogues and fragments, to repair pulmonary damage resulting from pulmonary microbial infections. The patent expires in 2023.TB4 is a synthetic version of a biologically active, naturally occurring peptide that has been shown, in pre-clinical studies, to be effective in accelerating dermal, ophthalmic, and myocardial wound healing. TB4 may also be important in other areas of tissue and organ repair, as well as tissue protection. RegeneRx is currently sponsoring five clinical trials and expects to report data later this year on several of these studies... RegeneRx Biopharmaceuticals' Press Release -
